WallStSmart

Elevai Labs, Inc. Common Stock (ELAB)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Elevai Labs, Inc. Common Stock generates 71% more annual revenue ($1.27M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. ELAB earns a higher WallStSmart Score of 25/100 (F).

ELAB

Avoid

25

out of 100

Grade: F

Growth: 2.7Profit: 2.5Value: 5.0Quality: 4.0
Piotroski: 2/9Altman Z: -2.92

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ELAB1 strengths · Avg: 10.0/10
Price/BookValuation
0.2x10/10

Reasonable price relative to book value

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

ELAB4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$7.00M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ELAB

The strongest argument for ELAB centers on Price/Book.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : ELAB

The primary concerns for ELAB are EPS Growth, Market Cap, Profit Margin.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

ELAB is growing revenue faster at -45.8% — sustainability is the question.

ELAB generates stronger free cash flow (-3M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ELAB scores higher overall (25/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Elevai Labs, Inc. Common Stock

HEALTHCARE · BIOTECHNOLOGY · USA

Elevai Labs, Inc. (Ticker: ELAB) is an innovative technology firm specializing in artificial intelligence and machine learning solutions that drive transformative efficiencies in various industries, notably healthcare and finance. By leveraging sophisticated data analytics platforms, Elevai Labs empowers organizations to make informed decisions and unlock actionable insights from intricate datasets. Positioned strategically within the burgeoning tech landscape, the company is poised to leverage emerging market trends, offering substantial value and operational improvements to clients and stakeholders alike. Its commitment to advancing AI-driven technologies underscores Elevai Labs' potential for sustainable growth and competitive advantage.

Visit Website →

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?